Arcutis Biotherapeutics, Inc.

Stage 3 · Topping · week 6

As of Oct 22, 2026, Arcutis Biotherapeutics is in Stage 3, the topping phase, now in week 6 (since Sep 14, 2026). It closed at $32.20, 1.9% below its 52-week high and above its 200-day average, which is falling.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. More about the company

$32.20

+1.32% today

$4.0B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is ARQT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S2 25w

S2 30w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 1w → S4 21w → S1 7w → S2 10w → S3 9w → S2 12w → S3 8w → S2 25w → S3 7w → S2 30w → S3 13w → S4 6w → S1 5w → S2 6w → S3 6w current

Total tracked: 166 weeks across 16 stage runs.

ARQT among Biotechnology84th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…84	ARQTArcutis Biotherapeutics, Inc.	Stage 3 · wk 6	88	+22.1%

vs 52W High

-1.9%

$19.50 lo$32.82 hi

Near 52W high, distribution zone

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 6

1w13w26w

Week 6, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

28.1%

200 DMA: $25.13 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.78x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+22.1%

+17.7%

+40.9%

YTD

+11.0%

+56.0%

Scan Membership

Breakout Watch

Latest: 2024-12-03

5 appearances in last 60 days. First seen: 2021-01-25.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 6 · Vol 0.78x

2026-10-21S3

Wk 6 · Vol 0.53x

2026-10-20S3

Wk 6 · Vol 1.73x

2026-10-19S3

Wk 6 · Vol 2.29x

2026-10-16S3

Wk 5 · Vol 0.70x

2026-10-15S3

Wk 5 · Vol 1.57x

2026-10-14S3

Wk 5 · Vol 0.65x

2026-10-13S3

Wk 5 · Vol 0.75x

2026-10-12S3

Wk 5 · Vol 0.62x

2026-10-09S3

Wk 4 · Vol 0.69x

2026-10-08S3

Wk 4 · Vol 1.05x

2026-10-07S3

Wk 4 · Vol 0.70x

Moving averages & range

50 DMA

$25.98

200 DMA

$25.13

52W High

$32.82

52W Low

$19.50

5D Low

$28.82

Resistance levels (recent highs)

20d High

$32.82

60d High

$32.82

120d High

$32.82

250d High

$32.82

Next resistance

+1.9%

to 20d High

P/E (TTM)

146.4

Forward 24.1

ROE

+15.9%

Profit margin +6.1%

Dividend Yield

0.00%

P/B 18.3

Arcutis Biotherapeutics: quick answers

What stage is Arcutis Biotherapeutics in?

As of Oct 22, 2026, Arcutis Biotherapeutics (ARQT) is in Stage 3, the topping phase. It entered Stage 3 on Sep 14, 2026 and is in week 6. What the four stages mean

Is Arcutis Biotherapeutics in an uptrend?

Its uptrend has stalled. Arcutis Biotherapeutics is in Stage 3, the topping phase that follows an advance. It trades 28.1% above its 200-day average, which is falling.

How far is Arcutis Biotherapeutics from its 52-week high?

Arcutis Biotherapeutics closed at $32.20 on Oct 22, 2026, 1.9% below its 52-week high of $32.82. Its 52-week low is $19.50.

How has Arcutis Biotherapeutics performed over the past year?

As of Oct 22, 2026, Arcutis Biotherapeutics is up 56.0% over the past year and up 11.0% so far in 2026.

Which sector and industry is Arcutis Biotherapeutics in?

Arcutis Biotherapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.